Results 1 to 3 of 3

Thread: RaphaLX

  1. #1
    Forum Member
    Join Date
    Jan 2020

    Lightbulb RaphaLX

    do you have knowledge about this investigational drug - RaphaLX.

    they seem pretty confident in this drug

    " RaphaLX™ is the company's flagship product that has been granted Orphan Drug Designation (ODD) by the FDA to treat ALS (amyotropic lateral sclerosis). It is a breakthrough formulation derived from human gut bacteria (microbiome), which in human studies has been observed to slow down the progression of the disease and in certain cases reverse the condition"

    and I found this :

  2. #2
    Forum Member nunhead_man's Avatar
    Join Date
    Jul 2017
    Good morning Timm

    I looked in because Rapha is a cycling brand in the UK!

    This looks like another route to reduce glutamate and I guess this is to be welcomed but I can't see any clinical trial data.

    Perhaps somebody else will come along in a minute with that information?


    ​Diagnosed 03/2015. Limb onset (arm) sporadic ALS/MND.
    MND hitting - now 50% left arm and 90% right arm, plus other bits including left shoulder

    "Things turn out the best for people who make the best of the way things turn out"

  3. #3
    Forum Member Kayleigh's Avatar
    Join Date
    Nov 2018
    So far, a small pilot study has been carried out.

    Although the results are of limited value, they are promising enough for further trials to take place (as explained under the heading 'Conclusions') ...


    Best wishes
    Last edited by Kayleigh; 5th February 2020 at 15:18.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts